GlaxoSmithKline is paying $176m for a 10% stake in University of Tübingen's RNA drug developer in connection with a strategic partnership agreement.

CureVac, a Germany-based RNA therapy spinout of Eberhard Karls University of Tübingen, signed a strategic partnership agreement with pharmaceutical firm GlaxoSmithKline (GSK) today that will include a €150m ($176m) equity investment.
GSK will also make a $141m upfront cash payment to CureVac and a reimbursable one-time payment of $35m to secure manufacturing capacity upon certification of a facility the company currently has under construction. The deak will give GSK a 10% stake in CureVac.
Founded in 2000, CureVac…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in